Full Press Release Details
FDA Approves Biogen Idec’s ALPROLIX™, the First Hemophilia B Therapy to Reduce Bleeding Episodes with Prophylactic Infusions Starting at Least a Week Apart.
BIIB
FDA Approves Biogen Idec’s ALPROLIX™, the First Hemophilia B Therapy to Reduce Bleeding Episodes with Prophylactic Infusions Starting at Least a Week Apart
Key Takeaway: FDA Approves Biogen Idec’s ALPROLIX™, the First Hemophilia B Therapy to Reduce Bleeding Episodes with Prophylactic Infusions Starting at Least a Week Apart